Potent inhibition of in vivo angiogenesis and tumor growth by a novel cyclooxygenase-2 inhibitor, enoic acanthoic acid

Hye Jin Jung, Joong Sup Shim, Young Ger Suh, Young Myeong Kim, Mayumi Ono, Ho Jeong Kwon

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Recent studies have shown that cyclooxygenase-2 is crucially involved in angiogenesis. In fact, several specific cyclooxygenase-2 inhibitors suppress angiogenesis in vivo, suggesting that cyclooxygenase-2 is a promising target for the treatment of angiogenesis-related diseases. In the present study we investigate the activity of a new cyclooxygenase-2 inhibitor, enoic acanthoic acid (EAA), which was synthesized from the known natural cyclooxygenase-2 inhibitor, acanthoic acid (AA). The demonstration of a high correlation between EAA- and celecoxib-induced gene expression signatures in microarray experiments validated the specificity of EAA on cyclooxygenase-2. In angiogenesis assays, EAA potently inhibited basic fibroblast growth factor-induced invasion and tube formation of bovine aortic endothelial cells in vitro. Moreover, this inhibitor prevented both neovascularization of the chorioallantoic membrane of growing chick embryo and basic fibroblast growth factor-induced mouse corneal angiogenesis in vivo. EAA also significantly suppressed the growth of bladder tumors in a mouse model, showing better antitumor activity than celecoxib. Furthermore, gelatin zymogram analysis revealed that EAA potently inhibited the activities of matrix metalloproteinase 2 and 9. These results clearly demonstrate that EAA is a promising agent for the prevention and treatment of angiogenesis-related diseases including cancer.

Original languageEnglish
Pages (from-to)1943-1948
Number of pages6
JournalCancer Science
Volume98
Issue number12
DOIs
Publication statusPublished - 2007 Dec 1

Fingerprint

Cyclooxygenase 2 Inhibitors
Celecoxib
Growth
Neoplasms
Cyclooxygenase 2
Fibroblast Growth Factor 2
Corneal Neovascularization
Chorioallantoic Membrane
acanthoic acid
Matrix Metalloproteinase 2
Matrix Metalloproteinase 9
Chick Embryo
Gelatin
Transcriptome
Urinary Bladder Neoplasms
Endothelial Cells

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Jung, Hye Jin ; Shim, Joong Sup ; Suh, Young Ger ; Kim, Young Myeong ; Ono, Mayumi ; Kwon, Ho Jeong. / Potent inhibition of in vivo angiogenesis and tumor growth by a novel cyclooxygenase-2 inhibitor, enoic acanthoic acid. In: Cancer Science. 2007 ; Vol. 98, No. 12. pp. 1943-1948.
@article{566db8b404484348a2a22d25e4136732,
title = "Potent inhibition of in vivo angiogenesis and tumor growth by a novel cyclooxygenase-2 inhibitor, enoic acanthoic acid",
abstract = "Recent studies have shown that cyclooxygenase-2 is crucially involved in angiogenesis. In fact, several specific cyclooxygenase-2 inhibitors suppress angiogenesis in vivo, suggesting that cyclooxygenase-2 is a promising target for the treatment of angiogenesis-related diseases. In the present study we investigate the activity of a new cyclooxygenase-2 inhibitor, enoic acanthoic acid (EAA), which was synthesized from the known natural cyclooxygenase-2 inhibitor, acanthoic acid (AA). The demonstration of a high correlation between EAA- and celecoxib-induced gene expression signatures in microarray experiments validated the specificity of EAA on cyclooxygenase-2. In angiogenesis assays, EAA potently inhibited basic fibroblast growth factor-induced invasion and tube formation of bovine aortic endothelial cells in vitro. Moreover, this inhibitor prevented both neovascularization of the chorioallantoic membrane of growing chick embryo and basic fibroblast growth factor-induced mouse corneal angiogenesis in vivo. EAA also significantly suppressed the growth of bladder tumors in a mouse model, showing better antitumor activity than celecoxib. Furthermore, gelatin zymogram analysis revealed that EAA potently inhibited the activities of matrix metalloproteinase 2 and 9. These results clearly demonstrate that EAA is a promising agent for the prevention and treatment of angiogenesis-related diseases including cancer.",
author = "Jung, {Hye Jin} and Shim, {Joong Sup} and Suh, {Young Ger} and Kim, {Young Myeong} and Mayumi Ono and Kwon, {Ho Jeong}",
year = "2007",
month = "12",
day = "1",
doi = "10.1111/j.1349-7006.2007.00617.x",
language = "English",
volume = "98",
pages = "1943--1948",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "12",

}

Potent inhibition of in vivo angiogenesis and tumor growth by a novel cyclooxygenase-2 inhibitor, enoic acanthoic acid. / Jung, Hye Jin; Shim, Joong Sup; Suh, Young Ger; Kim, Young Myeong; Ono, Mayumi; Kwon, Ho Jeong.

In: Cancer Science, Vol. 98, No. 12, 01.12.2007, p. 1943-1948.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Potent inhibition of in vivo angiogenesis and tumor growth by a novel cyclooxygenase-2 inhibitor, enoic acanthoic acid

AU - Jung, Hye Jin

AU - Shim, Joong Sup

AU - Suh, Young Ger

AU - Kim, Young Myeong

AU - Ono, Mayumi

AU - Kwon, Ho Jeong

PY - 2007/12/1

Y1 - 2007/12/1

N2 - Recent studies have shown that cyclooxygenase-2 is crucially involved in angiogenesis. In fact, several specific cyclooxygenase-2 inhibitors suppress angiogenesis in vivo, suggesting that cyclooxygenase-2 is a promising target for the treatment of angiogenesis-related diseases. In the present study we investigate the activity of a new cyclooxygenase-2 inhibitor, enoic acanthoic acid (EAA), which was synthesized from the known natural cyclooxygenase-2 inhibitor, acanthoic acid (AA). The demonstration of a high correlation between EAA- and celecoxib-induced gene expression signatures in microarray experiments validated the specificity of EAA on cyclooxygenase-2. In angiogenesis assays, EAA potently inhibited basic fibroblast growth factor-induced invasion and tube formation of bovine aortic endothelial cells in vitro. Moreover, this inhibitor prevented both neovascularization of the chorioallantoic membrane of growing chick embryo and basic fibroblast growth factor-induced mouse corneal angiogenesis in vivo. EAA also significantly suppressed the growth of bladder tumors in a mouse model, showing better antitumor activity than celecoxib. Furthermore, gelatin zymogram analysis revealed that EAA potently inhibited the activities of matrix metalloproteinase 2 and 9. These results clearly demonstrate that EAA is a promising agent for the prevention and treatment of angiogenesis-related diseases including cancer.

AB - Recent studies have shown that cyclooxygenase-2 is crucially involved in angiogenesis. In fact, several specific cyclooxygenase-2 inhibitors suppress angiogenesis in vivo, suggesting that cyclooxygenase-2 is a promising target for the treatment of angiogenesis-related diseases. In the present study we investigate the activity of a new cyclooxygenase-2 inhibitor, enoic acanthoic acid (EAA), which was synthesized from the known natural cyclooxygenase-2 inhibitor, acanthoic acid (AA). The demonstration of a high correlation between EAA- and celecoxib-induced gene expression signatures in microarray experiments validated the specificity of EAA on cyclooxygenase-2. In angiogenesis assays, EAA potently inhibited basic fibroblast growth factor-induced invasion and tube formation of bovine aortic endothelial cells in vitro. Moreover, this inhibitor prevented both neovascularization of the chorioallantoic membrane of growing chick embryo and basic fibroblast growth factor-induced mouse corneal angiogenesis in vivo. EAA also significantly suppressed the growth of bladder tumors in a mouse model, showing better antitumor activity than celecoxib. Furthermore, gelatin zymogram analysis revealed that EAA potently inhibited the activities of matrix metalloproteinase 2 and 9. These results clearly demonstrate that EAA is a promising agent for the prevention and treatment of angiogenesis-related diseases including cancer.

UR - http://www.scopus.com/inward/record.url?scp=35549000462&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35549000462&partnerID=8YFLogxK

U2 - 10.1111/j.1349-7006.2007.00617.x

DO - 10.1111/j.1349-7006.2007.00617.x

M3 - Article

C2 - 17888030

AN - SCOPUS:35549000462

VL - 98

SP - 1943

EP - 1948

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 12

ER -